Skip to main content

Table 3 Recent clinical trials for PARP, ATR, DNA-PK, WEE1, and CHK1 inhibitors: monotherapy and combination therapy

From: Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

Target Agent Intervention Cancer Type Phase identifier
PARP Olaparib Olaparib Breast and ovarian cancer IV NCT04330040
Olaparib + Paclitaxel + Durvalumab Advanced gastric cancer II NCT03579784
Olaparib + Abiraterone Prostate cancer III NCT03732820
Olaparib + Durvalumab Bladder cancer II NCT03534492
Olaparib + Temozolomide Colorectal cancer II NCT04166435
Niraparib Niraparib Pancreatic cancer II NCT03601923
Niraparib + Osimertinib Lung cancer I NCT03891615
Niraparib + Dostarlimab Ovarian cancer III NCT03602859
Niraparib + MGD013 Gastric and gastroesophageal junction cancer I NCT04178460
Niraparib + Dostarlimab Cervix cancer II NCT04068753
Rucaparib Rucaparib Endometrial cancer II NCT03617679
Rucaparib + Nivolumab Biliary tract cancer II NCT03639935
Rucaparib + Radiotherapy Breast cancer I NCT03542175
Rucaparib + Copanlisib Prostate cancer I NCT04253262
Rucacparib + Enzalutamide + Abiraterone Prostate cancer I NCT04179396
Talazoparib Talazoparib Leukemia I NCT03974217
Talazoparib + Avelumab Breast cancer I NCT03964532
Talazoparib + Radiotherapy Gynecologic cancer I NCT03968406
Talazoparib + ASTX727 Breast cancer I NCT04134884
Talazoparib + Avelumab Lung cancer II NCT04173507
Talazoparib + Axitinib Kidney cancer I/II NCT04337970
Talazoparib + Atezolizumab Lung cancer II NCT04334941
Talazoparib + Gedatolisib Breast cancer II NCT03911973
ATR Berzosertib (M6620) Berzosertib + Radiotherapy Lung cancer I NCT02589522
Berzosertib + Radiotherapy Breast cancer I NCT04052555
Berzosertib + Topotecan Lung cancer I/II NCT02487095
Berzosertib + Topotecan Hydrochloride Lung cancer II NCT03896503
Berzosertib + Carboplatin + Docetaxel Prostate cancer II NCT03517969
AZD6738 AZD6738 + Radiotherapy Advanced solid tumors I NCT02223923
AZD6738 + Olaparib Gynecologic cancer II NCT04065269
AZD6738 + Olaparib + Durvalumab Breast cancer II NCT03740893
AZD6738 + Acalabrutinib Chronic lymphocytic leukemia I/II NCT03328273
AZD6738 + Durvalumab Biliary tract cancer II NCT04298008
BAY1895344 BAY1895344 Advanced solid tumors I NCT03188965
BAY1895344 + Pembrolizumab Advanced solid tumors I NCT04095273
BAY1895344 + Niraparib Ovarian cancer I NCT04267939
M4344 M4344 + Niraparib Ovarian cancer I NCT04149145
M4344 + Carboplatin Advanced solid tumors I NCT02278250
DNA-PK CC-115 CC-115 Advanced solid tumors I NCT01353625
CC-115 + Enzalutamide Prostate cancer I NCT02833883
AZD7648 AZD7648 + Olaparib + Pegylated Liposomal Doxorubicin Advanced solid tumors I/II NCT03907969
M9831 (VX-984) M9831 Advanced solid tumors I NCT02644278
Nedisertib (M3814) Nedisertib + Pegylated Liposomal Doxorubicin Hydrochloride Ovarian cancer I NCT04092270
Nedisertib + Avelumab + Radiotherapy Hepatobiliary cancer I/II NCT04068194
Nedisertib + Avelumab + Radiotherapy Advanced solid tumors I NCT03724890
WEE1 Adavosertib (AZD1775) Adavosertib Advanced solid tumors I NCT01748825
Adavosertib Advanced solid tumors II NCT03253679 / NCT03284385
Adavosertib + Gemcitabine + Cisplatin + Carboplatin Advanced solid tumors I NCT00648648
Adavosertib + Olaparib Ovarian, primary peritoneal, and fallopian tube cancer II NCT03579316
Adavosertib + Olaparib + AZD6738 Breast cancer II NCT03330847
Adavosertib + Irinotecan Advanced solid tumors I/II NCT02095132
Adavosertib + Cisplatin + Radiotherapy Cervical, vaginal, and uterine cancer I NCT03345784
Adavosertib + Temozolomide + Radiotherapy Glioblastoma I NCT01849146
CHK1 SRA737 SRA737 Advanced solid tumors I/II NCT02797964
SRA737 + Gemcitabine + Cisplatin Advanced solid tumors I/II NCT02797977
Prexasertib (LY2606368) Prexasertib Advanced solid tumors I NCT01115790
Prexasertib Lung cancer II NCT02735980
Prexasertib Breast, ovarian, and prostate cancer II NCT02203513
Prexasertib + Cisplatin + Cetuximab + Radiotherapy Head and neck cancer I NCT02555644